Jefferies Downgrades Allergan (AGN) to Hold
More News related to AGN
- Validity of Allergan Patents Acknowledged by Jan Marini in Settlement of Allergan's Patent Infringement Suit Against Jan Marini Skin Research, Inc.
- Citi Downgrades Allergan (AGN) to Hold
- Legendary Sports Icons, Nadia Comaneci and Mark Spitz, Support Your Personal Best Public Education Campaign
- QLT completes divestment of Aczone(R) to Allergan for USD$150 million
- Allergan Completes Acquisition of Aczone Gel 5%
More News related to Downgrades
- Matrix USA Rating Changes 7/18
- Piper Jaffray Downgrades Infinity Property and Casualty (IPCC) To Neutral
- Stanford Downgrades ViroPharma (VPHM) to Hold
- SemGroup Energy (SGLP) Gets Cut In Half
- Stanford Downgrades ValueClick (VCLK) to Hold
Jefferies downgrades Allergan (NYSE: AGN) from Buy to Hold with a $62 price target.
Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide.
Related Categories
DowngradesStocks Mentioned
-0.42Related Entities
Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
